What does nine-valent hpv mean?

Nine-valent HPV vaccine is used to prevent cervical cancer caused by human papillomavirus (HPV) infection, which can prevent more than 90% of cervical cancer. The vaccine was approved for marketing in the United States on 20 14.

On April 28th, 20 18, the State Administration of Pharmaceutical Products conditionally approved the marketing of nine-valent HPV vaccine for preventing cervical cancer in China. Vaccination is primary prevention and screening is secondary prevention, both of which are equally important. Therefore, screening measures for cervical cancer should not be relaxed because of vaccination.

Related information:

Nine-valent HPV vaccine has good immunogenicity. After three doses of inoculation, the positive conversion rate of serum antibodies of related types can almost reach 100%. After vaccination 1 month, the peak of the geometric average titer of antibody can reach 100 times of the antibody level after natural infection, and in the next two months, the value will drop to 10 times, and will remain in the platform period.

The antibody level of the vaccine can be maintained for at least 4 years. In the clinical trial of the effectiveness of the nine-valent HPV vaccine, the main end points are the persistent infection of related human papillomavirus type, genital warts of related human papillomavirus type, cervical intraepithelial neoplasia (CIN), external genital or vaginal intraepithelial neoplasia (VIN or VaIN).